Abstract
Despite the growing accessibility of clinical sequencing, functional interpretation of variants remains a major hurdle to molecular diagnostics of Mendelian diseases. We aimed to describe a new adult-onset myopathy with muscle weakness and hyperCKemia caused by a nonsense variant in muscular LMNA-interacting protein (MLIP). Following RNA-sequencing, differential expression analysis uncovered a significant downregulation of this gene, which had a surprisingly mild effect on MLIP protein expression. RT-PCR and long-read sequencing (LRS) both support an important transcriptome shift in the patient, where decreased MLIP levels are seemingly due to nonsense-mediated decay of transcripts containing the exon 5 mutation. Moreover, a compensatory mechanism upregulates the functionally lacking isoforms and generates novel transcripts. These results support the recently discovered clinical implications of MLIP variants in myopathies, highlighting for the first time its relevance in adult-onset cases. These results also underline the power of LRS as a tool for the functional assessment of variants of unknown significance (VUS), as well as the definition of accurate isoform profile annotations in a tissue-specific manner.
Subject terms: RNA sequencing, Transcriptomics, RNA splicing, Mutation
Introduction
Myopathies and muscular dystrophies are a large group of progressive genetic neuromuscular diseases that emerge from dysfunctions and irregularities within the muscular tissue, affecting its general integrity, structure, and molecular activity1. Gradual degeneration of the muscle fibers prompts variable clinical presentation, generally including but not restricted to; muscular weakness, cramps, stiffness, posture instability, and ultimately leading to a probable loss of motor functions1. Due to the notable heterogeneity of these pathologies, the association of putative disease variants with phenotypes is highly complex. This hinders the ability to achieve an official diagnosis, as further genetic and molecular characterization is often required but strenuous. This drawback is amplified in genes that have yet to be extensively studied from a functional standpoint and have not yet been associated with muscle-related disorders.
Muscular LMNA-interacting protein (MLIP) has only recently been identified as a cause of autosomal recessive myopathy with rhabdomyolysis, myalgia, and elevated serum creatine kinase2. The report highlights eight different variants in the MLIP gene within seven pediatric biallelic carriers, all of which are expected to cause major protein alterations: four frameshifts leading to premature stop codons, two stop-gains, as well as two alternative splicings which, respectively, induce an exon skipping and a premature stop-codon2. While literature concerning the MLIP function is not extensive, it is generally thought to play a role in the regulation of transcriptional activators in pathways such as the Akt/mTOR/FOXO1 cardiac stress response3,4 and is known to interact with lamin A/C (LMNA)5, which is a largely studied cause of muscle diseases6,7. Interestingly, all the investigated mutations localize near exon 4 or 9, resulting in a loss of the nuclear localization signal (NLS) and/or the AT-Hook DNA binding motif, respectively5,8. It has been suggested that such major changes theoretically result in a considerable functional effect, therefore likely leading to dysregulations of various important biological pathways2.
Considering the group had access to a small cohort of patients with similar variants, they were able to demonstrate functional changes through the consistent reduction in mRNA levels of MLIP. The quantitative droplet digital PCR suggests nonsense-mediated decay, which should ultimately result in lowered protein levels and guided our initial hypothesis. In a single patient (Z46) exhibiting comparable but rather different phenotypes, a more in-depth functional assessment is required to assess the relevance of MLIP as the best candidate to explain the distal myopathy. Hence, on top of standard validation through western blot, quantitative PCR (qPCR), and reverse transcriptase PCR (RT-PCR), we propose long-read sequencing (LRS) as a potent clinical tool to identify accurate tissue-relevant transcripts, as well as being indicative of mRNA level changes in an isoform-specific manner.
Results
Our patient presented around age 50 with distal (mainly dorsiflexors) more than proximal leg weakness and distal hand weakness. Despite a late-onset of debilitating symptoms, careful history revealed that he had consulted around age 5 for poor sports performance (unable to run as fast as his peers and to ice skate) but never received a clear diagnosis. The absence of muscle disorders or consanguinity in the familial history was also noted. By age 60 he had developed exaggerated lumbar lordosis and a Trendelenburg gait. Muscle pain and cramping were observed but no rhabdomyolysis was reported. Evaluation of basal serum creatine kinase did reveal a significant increase (888 U/L) that lands in the observed hyperCKemia range of 300–3000 U/L2. Similar to the pediatric cases, our patient does not exhibit cardiac abnormalities, which could have been expected considering MLIP known role in adaptation to cardiac stressors3. Muscle biopsy showed only a single necrotic fiber, but many fibers with internal nuclei, fiber-size variability with hypertrophied fibers, type 1 fiber atrophy, and type 2 fibers containing small rimmed vacuoles. EMG demonstrated small polyphasic motor units with some fibrillations and positive sharp waves. ECG, ECHO, and a 24 h Holter monitor were also conducted but the results were unremarkable.
Following inconclusive gene panel testing (Supplementary Table 1)9, RNA-sequencing served as a diagnostic tool for this complex case, where variant calling data revealed a nonsense homozygous mutation in the exon 5 of MLIP (NM_001281747.2: p.Gln762Ter, c.2284 C > T). This finding was confirmed by Sanger sequencing of the patient’s DNA. Upon performing a differential expression analysis using DESeq, a highly significant decrease can be observed in MLIP expression (Fig. 1a)10. An exon usage analysis was performed not only to identify alternative splicing in Z46 but also to confirm the global decrease of MLIP expression (Supplementary Fig. 2). A pathway enrichment analysis, aimed at identifying additional validation targets and molecular changes, yielded no significant results regarding MLIP known functions or main interaction partners11,12.
The downregulation of MLIP was consolidated using two qPCR probes, targeting either transcript that specifically contains the nonsense variant, or accounting for all isoforms. The latter revealed a similar tendency to the RNA-sequencing: although more modest, a decrease of about 40% of MLIP transcripts is observed (Fig. 1b). Interestingly, a considerable upregulation of LMNA was also noted. Regarding the western blot, preliminary results showed a correlating downregulation of MLIP for the 27 kDa isoform (ENST00000370876.6), which contains neither exon 4 or 5. A negligible change for the 50 kDa (ENST00000274897.9), which theoretically carries the exon 5 mutation and should not be produced, was unexpected (Fig. 1c). Unfortunately, NLS containing isoforms (ENST00000502396.5 and ENST00000514921.5) could not be quantified, as the extraction was not specific to nuclear proteins, leading to very light bands for both samples (Supplementary Fig. 3). Again, increased levels of LMNA can be observed, especially lamin A, exhibiting a nearly two-fold increase in comparison to control (Fig. 1d).
RT-PCR was performed between the 3rd and 8th exon of MLIP, capturing most muscle transcripts while keeping the interpretation simple. Although qualitative, gel migration revealed a clear alteration of the patient’s transcript balance: while the second to the lowest band is the main isoform in the control, it is considerably decreased in Z46 compared to other visible transcripts, which appear upregulated (Fig. 2a). When correlating amplicons with the GTEx muscle isoforms repertoire, we supposed the presence of transcripts ENST00000502396.5, ENST00000274897.9, and a novel isoform containing exons 3–6–7–8, making it the only fragment that does not carry the variant.
LRS subsequently allowed isoform-specific quantification of all known transcripts. Data reveal a near-perfect correlation with RT-PCR results (Fig. 2b), where a drastic downregulation of isoforms containing exon 5 is milder when exon 4 is co-expressed, and the proportional expression of transcripts that do not carry the mutation is significantly increased (Fig. 2c, d). Additionally, we discovered that the patient seems to produce and conserve novel transcripts that contain exon 4, but not 5. Furthermore, they’re not the only novel transcripts that our analysis revealed: while ENST00000502396.5 and ENST00000370876.6 are indeed the main muscle isoforms, ENST00000447846.6, ENST00000514433.1, as well as two other newly identified transcripts (labeled Novel Transcript 1 and 2) exhibit levels comparable to ENST00000274897.9 in both samples (Fig. 2c). Ratio quantification utilized data from all the isoforms, but only high-confidence transcripts are presented as potential novel isoforms, none of which exhibit alternative splicing that differs from canonical reading frames.
Discussion
In this report, we used RNA-sequencing in a clinical setting after standard gene panels failed to identify candidates for the patient’s pathology. While variant calling did not find pathogenic mutations in relevant myopathy-related genes (Supplementary Table 1), a novel homozygous variant causing an early truncation of MLIP on both alleles was predicted to have a highly negative effect on its function. Although there were very few studies about MLIP function, and no links to any pathology, numerous factors hinted at the relevance of this locus to myopathies. A muscle-specific expression pattern and a proven interaction with LMNA5, combined with the high in silico pathogenicity score as well as the decreased mRNA expression in transcriptomic data prompted further investigation of the variant. Very recently, an article identified MLIP as disease-causing in a cohort of patients exhibiting early-onset myopathy with rhabdomyolysis2. Similar to the pediatric variants, the premature translation termination in exon 5 is predicted to importantly modify both the structure and the functions of the protein by inducing a biallelic absence of its AT-Hook DNA binding motif8. Indeed, current literature states that in addition to being present in two of the three main muscle isoforms, exon 5 is mutually inclusive to transcripts containing exon 4. Considering the latter contains the NLS5, the mutation reported in our patient could potentially hinder MLIP nuclear role. Nevertheless, it seems the localization of variants affects phenotypic presentation, as clinical examination findings are considerably different between our patient and the younger cohort.
One of the advantages of RNA-sequencing is the functional insight that can be gathered from expression data13. It has been hypothesized that dysfunctional MLIP potentially disrupts multiple molecular pathways, such as causing an overactivation of the Akt/mTOR or FOXO1 pathway in correlation to a reduced adaptive response to stressors3,4. Unfortunately, there was no significant enrichment of the genes related to those networks in our data. Similarly, nothing noteworthy can be found in regard to both glycolysis and gluconeogenesis2. Observable molecular changes include the activation of the host immune system, which indicates probable progressive necrosis of unhealthy muscle cells14. The Syndecan-1 pathway also appears significantly upregulated, which might play a key role in protecting against cardiac phenotypes15. While our study gives interesting insights into potential molecular consequences of MLIP mutations, the analysis was performed on a single patient, and conclusive results surrounding pathway enrichments require more samples.
As the quantification of mRNA expression is an important step of the functional validation, we made sure to capture changes accurately by using two probes simultaneously. While a larger decrease could have been expected following the differential expression analysis, the results correlate with the general decrease of MLIP mRNA in muscle tissues. These non-significative observations support our hypothesis that while MLIP mRNA likely undergoes nonsense-mediated decay, the cells attempt to compensate for truncated proteins by specifically splicing transcripts to contain exon 4 and produce the nuclear protein. This would rationalize the considerable upregulation of LMNA, presumably as a compensatory mechanism for the deficiency of its direct partner5. Regarding protein levels, only two of the four visible isoforms can be quantified but results once again correlate with previous experiments: MLIP expression is decreased, causing upregulation of LMNA to compensate for the likely diminished yet necessary interaction between the nuclear proteins. The presence of unaltered MLIP proteins in the patient was unexpected. While the C-terminal antibody does not allow detection of truncated proteins, normal bands in Z46 prove that muscle cells find a way to produce nearly full-length proteins despite the stop-gain. Two hypothetical explanations for this phenomenon are an elevated proportion of stop-codon read-through in response to reduced functional MLIP levels16, and alternative splicing allowing non-canonical excision of the exon 5 specifically17,18. These partial escape mechanisms, if observed, are likely to play a role in the milder phenotypes of our patient compared to pediatric cases.
It has been shown that distinct isoforms can have tissue-specific functions, hence the aim of evaluating changes in transcripts ratio19. The qualitative RT-PCR was key in constructing the hypothesis of conflicting cellular mechanisms: nonsense-mediated decay appears to oppose the upregulation of the functionally relevant MLIP transcripts in response to the deficiency of proteins capable of translocating to the nucleus. This came from visible downregulation of transcripts containing exon 5, while other isoforms are promoted in comparison. As transcripts containing the NLS theoretically always carry the variant, they require a substantial transcription upregulation to overcome concurrent mRNA decay.
LRS data confirmed our suppositions, clearly highlighting a significant decrease of transcripts containing the variant as well as a proportional increase of other transcripts, particularly those containing exon 4. In fact, not only is it observable in canonical isoforms, but Z46 also expresses novel transcripts containing exon 4 without its usual splice partner. While those new isoforms represent a minority of the MLIP transcriptome, they confirm the hypothesis that compensatory alternative splicing allows the production of nearly full-length proteins. Another unexpected result was that additional unreported non-canonical transcripts were present in non-negligible amounts for both samples. This suggests that their expression would not be restricted to our study and that the tissue-specific alternative splicing of MLIP might be even more extensive than what current literature suggests. While further assessment is required to confirm these findings, they prompt the relevance of performing LRS on more samples. Furthermore, we believe the approach is very powerful and could uncover similar results in a broader range of pathologies, underlining its vast potential in clinical contexts. Indeed, while LRS currently offers less accurate base calling than its short-read homolog, its true strength lies in the assembly of de novo tissue-specific transcript annotations, which hints toward a considerable improvement of current knowledge regarding existing transcriptomic splicing20. While long-read methods are still in an early developmental stage, community enthusiasm has led to consistent improvement surrounding the approach and related bioinformatics tools. Therefore, it would not be surprising if LRS applications reach a largescale, whole-transcriptome level in the not-so-distant future.
Overall, our report of a biallelic nonsense mutation supports the implication of MLIP as a causative gene for myopathies with muscle weakness and hyperCKemia. The important element we highlight is that clinicians should consider MLIP mutations outside of pediatric cases, as adult-onset phenotypes, albeit milder, could ensue from functional changes in the protein. Indeed, clinical heterogeneity is to be expected in MLIP-related disorders, mainly due to its complex transcriptomic architecture. In that regard, LRS shall help define more accurate tissue-specific transcript annotations. Along with future cellular modeling of the mutations, it should give additional insights into the protein molecular functions. We strongly believe our findings should further assist clinicians in the diagnosis of patients carrying MLIP variants, but also in the assessment of functional effects of candidate variants, where available transcript annotations are potentially incomplete or inaccurate.
Methods
Patient
The proband was evaluated by an experienced neurologist (E.O.) and had a muscle biopsy as part of his clinical workup. The McGill University Health Centre Research Ethics Board approved the study. The proband signed an informed consent authorizing genetic analysis in a research setting.
RNA-sequencing
RNA was extracted from muscle biopsies using TRIzol. The sequencing library was prepared using the TruSeq stranded mRNA library preparation kit and sequenced on an Illumina HiSeq 2500 using 125 bp paired-end reads. Alignment was performed using STAR against a reference genome (hg19) before variant calling with GATK (v.3.7)21,22. VCF annotation utilized ANNOVAR databases and custom scripts23. Read counts were obtained using featureCounts prior to DESeq differential expression quantification. EnhancedVolcano was used to produce the plot24, DEXseq enabled the exon usage analysis25, and gene enrichment analysis was performed using GSEA10–12,26.
Reverse transcription polymerase chain reaction
cDNA was obtained following reverse transcription with SuperScript Vilo mix (Invitrogen, 11754050), and amplified with EasyTaq polymerase (TransGen Biotech, AP111–01) using custom primers GGGAATTCGAAGCAAACAAA; GGGGACCTTGAAGGAGAATC. Three nanograms of samples were loaded on a 2% E-gel with 500 ng of 1 Kb Plus E-gel DNA ladder.
Quantitative polymerase chain reaction
qPCR utilized four different TaqMan probes (Invitrogen): Hs00951675_m1 and Hs00370866_m1 respectively target the exon junctions 5–6 and 9–10 of MLIP. Hs00153462_m1 is specific to junctions 2–3 of LMNA. Hs03004310_g1 binds junction 1–2 of housekeeping gene RPS29 for data normalization. Expression levels were assessed through relative ΔΔCT quantification from the QuantStudio 6/7 System.
Western blot
Proteins were obtained from muscle tissues following TRIzol processing. Thirty micrograms of proteins were loaded on a gradient 4–15% polyacrylamide gel (Bio-Rad, 4561084). Samples were transferred on a PVDF membrane and blocked in 5% milk-PBS (30 min). Antibodies used in this report: MLIP rabbit-polyclonal (Invitrogen PA5–72759, 1:2000 dilution); LMNA rabbit-polyclonal (NEB 2026 S, 1:1000 dilution); GAPDH rabbit-monoclonal (NEB 5174 S, 1:1000 dilution); HRP anti-rabbit (Jackson ImmunoResearch 111–035–114, 1:10000 dilution). Primary antibodies incubation was done overnight at 4 °C with dilutions in 1% BSA-0.1% sodium azide-PBS, followed by 1 h incubation with secondary antibody solution. Proteins revelation with an ECL substrate kit was followed by chemiluminescence capture through the ChemiDoc System, and images were analyzed with the Image Lab 6.0.1 software.
Long-read sequencing
The library was prepared from total muscle RNA, reverse transcribed with the SuperScript Vilo mix, and amplified (30 cycles) using the LongAmp Taq DNA Polymerase (NEB, M0323S). Two sets of barcoded primers targeted exons 3 (TGGACTCCGAAGGGGAAGAT) and 11 (GGGCGAATTACTCCAGGCTT). The amplicons were incubated with the Exonuclease I (NEB, M0293S) for single-stranded DNA cleanup. The library was end prepped with the NEBNext Ultra II End Repair/dA-Tailing Module to allow AMX adapter ligation with the NEBNext Quick Ligation Module ligase (ONT, SQK-LSK109). Purification with AMPure XP beads preceded the final 1× dsDNA QuBit4 fluorometric quantification, which allowed concentration-specific multiplexing of samples. The library was loaded on a flow cell (FLO-MIN106) for MinION sequencing over a 24 h period. The final data were processed with Guppy high-accuracy base calling and demultiplexing, followed by the FLAIR pipeline27,28.
Reporting summary
Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Supplementary information
Acknowledgements
We would like to thank the patient for his willing participation in this study. We also thank Dr. Simon Grandjean Lapierre for his MinION Sequencing system, as well as Floriane Point and Dr. Karine Choquet for their helpful insights on setting up the LRS protocol. This project was supported by The Courtois Foundation, Fondation du Grand Défi Pierre Lavoie, and the Rare Disease Foundation. S.A. received a master’s degree fellowship from the Canadian Institute of Health Research and F.M. from the Neuroscience department of Université de Montréal. M.T. received a Junior 1 salary award from the Fond de recherche du Québec—Santé.
Author contributions
J.M. and S.A. contributed to the work equally. J.M.: Data acquisition, analysis, and interpretation (RT-qPCR, RT-PCR, western blot, and LRS). Wrote the manuscript. S.A.: Data acquisition, analysis, and interpretation (RNA-sequencing, RT-PCR, western blot, and LRS). Wrote the manuscript. F.M.: Data acquisition, analysis, and interpretation (RNA-sequencing and RT-qPCR). Reviewed the manuscript. J.C.: Data acquisition, analysis, and interpretation (RT-PCR and western blot). Reviewed the manuscript. V.T.: Bioinformatic pipelines (LRS). Reviewed the manuscript. E.B.: Bioinformatic pipelines (RNA-sequencing). Reviewed the manuscript. A.L.: Data acquisition and analysis (western blot). Reviewed the manuscript. J.K.: Pathological evaluation of muscle biopsy. Reviewed the manuscript. R.M., C.H.C., and E.K.F.: Clinical evaluation. Reviewed the manuscript. M.T.: Study design and data interpretation. Supervision of J.M., S.A., F.M., J.C., and V.T. Wrote the manuscript.
Data availability
Data that support the findings of this study are available from the corresponding author upon request. The sequencing data of this study were stored in NCBI Bio Project (PRJNA809363).
Competing interests
The authors declare no competing interests.
Footnotes
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
These authors contributed equally: Jean Mezreani, Sébastien Audet.
Supplementary information
The online version contains supplementary material available at 10.1038/s41525-022-00307-y.
References
- 1.Shieh PB. Muscular dystrophies and other genetic myopathies. Neurol. Clin. 2013;31:1009–1029. doi: 10.1016/j.ncl.2013.04.004. [DOI] [PubMed] [Google Scholar]
- 2.Lopes Abath Neto O, et al. MLIP causes recessive myopathy with rhabdomyolysis, myalgia and baseline elevated serum creatine kinase. Brain. 2021;144:2722–2731. doi: 10.1093/brain/awab275. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Huang ZP, et al. Cardiomyocyte-enriched protein CIP protects against pathophysiological stresses and regulates cardiac homeostasis. J. Clin. Invest. 2015;125:4122–4134. doi: 10.1172/JCI82423. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Cattin ME, et al. Deletion of MLIP (muscle-enriched A-type lamin-interacting protein) leads to cardiac hyperactivation of Akt/mammalian target of rapamycin (mTOR) and impaired cardiac adaptation. J. Biol. Chem. 2015;290:26699–26714. doi: 10.1074/jbc.M115.678433. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Ahmady E, et al. Identification of a novel muscle A-type lamin-interacting protein (MLIP) J. Biol. Chem. 2011;286:19702–19713. doi: 10.1074/jbc.M110.165548. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Charniot JC, et al. Functional consequences of an LMNA mutation associated with a new cardiac and non-cardiac phenotype. Hum. Mutat. 2003;21:473–481. doi: 10.1002/humu.10170. [DOI] [PubMed] [Google Scholar]
- 7.Muchir A, et al. Activation of MAPK pathways links LMNA mutations to cardiomyopathy in Emery-Dreifuss muscular dystrophy. J. Clin. Invest. 2007;117:1282–1293. doi: 10.1172/JCI29042. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Huang ZP, et al. CIP, a cardiac Isl1-interacting protein, represses cardiomyocyte hypertrophy. Circ. Res. 2012;110:818–830. doi: 10.1161/CIRCRESAHA.111.259663. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.González-Jamett, A. M., Bevilacqua, J. A. & Díaz, A. M. C. Hereditary Myopathies. In (Ed.), Muscle Cell and Tissue - Current Status of Research Field. 10.5772/intechopen.76076 (2018).
- 10.Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550. doi: 10.1186/s13059-014-0550-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA. 2005;102:15545–15550. doi: 10.1073/pnas.0506580102. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Mootha VK, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 2003;34:267–273. doi: 10.1038/ng1180. [DOI] [PubMed] [Google Scholar]
- 13.Widyastuti HP, Norden-Krichmar TM, Grosberg A, Zaragoza MV. Gene expression profiling of fibroblasts in a family with LMNA-related cardiomyopathy reveals molecular pathways implicated in disease pathogenesis. BMC Med. Genet. 2020;21:152. doi: 10.1186/s12881-020-01088-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Dalakas MC, Alexopoulos H, Spaeth PJ. Complement in neurological disorders and emerging complement-targeted therapeutics. Nat. Rev. Neurol. 2020;16:601–617. doi: 10.1038/s41582-020-0400-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Chaterji S, Lam CH, Ho DS, Proske DC, Baker AB. Syndecan-1 regulates vascular smooth muscle cell phenotype. PLoS ONE. 2014;9:e89824. doi: 10.1371/journal.pone.0089824. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Li C, Zhang J. Stop-codon read-through arises largely from molecular errors and is generally nonadaptive. PLoS Genet. 2019;15:e1008141. doi: 10.1371/journal.pgen.1008141. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Sibley CR, Blazquez L, Ule J. Lessons from non-canonical splicing. Nat. Rev. Genet. 2016;17:407–421. doi: 10.1038/nrg.2016.46. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Chiba M, Ariga H, Maita H. A splicing reporter tuned to non-AG acceptor sites reveals that luteolin enhances the recognition of non-canonical acceptor sites. Chem. Biol. Drug. Des. 2016;87:275–282. doi: 10.1111/cbdd.12656. [DOI] [PubMed] [Google Scholar]
- 19.Cattin ME, et al. Expression of murine muscle-enriched A-type lamin-interacting protein (MLIP) is regulated by tissue-specific alternative transcription start sites. J. Biol. Chem. 2018;293:19761–19770. doi: 10.1074/jbc.RA118.003758. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Amarasinghe SL, et al. Opportunities and challenges in long-read sequencing data analysis. Genome Biol. 2020;21:30. doi: 10.1186/s13059-020-1935-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Dobin A, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15–21. doi: 10.1093/bioinformatics/bts635. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Brouard JS, Schenkel F, Marete A, Bissonnette N. The GATK joint genotyping workflow is appropriate for calling variants in RNA-seq experiments. J. Anim. Sci. Biotechnol. 2019;10:44. doi: 10.1186/s40104-019-0359-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38:e164. doi: 10.1093/nar/gkq603. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Blighe, K., Rana, S. & Lewis, M. EnhancedVolcano: Publication-ready volcano plots with enhanced colouring and labeling. Preprint at https://github.com/kevinblighe/EnhancedVolcano (Bioconductor within R. R version 4.0.3., 2020).
- 25.Anders S, Reyes A, Huber W. Detecting differential usage of exons from RNA-seq data. Genome Res. 2012;22:2008–2017. doi: 10.1101/gr.133744.111. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30:923–930. doi: 10.1093/bioinformatics/btt656. [DOI] [PubMed] [Google Scholar]
- 27.Wick RR, Judd LM, Holt KE. Performance of neural network basecalling tools for Oxford Nanopore sequencing. Genome Biol. 2019;20:129. doi: 10.1186/s13059-019-1727-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Tang AD, et al. Full-length transcript characterization of SF3B1 mutation in chronic lymphocytic leukemia reveals downregulation of retained introns. Nat. Commun. 2020;11:1438. doi: 10.1038/s41467-020-15171-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
Data that support the findings of this study are available from the corresponding author upon request. The sequencing data of this study were stored in NCBI Bio Project (PRJNA809363).